Elan Gorshein, DO, JD, MPH
Assistant Professor of Medicine (Hematology)Cards
About
Research
Publications
2026
Dietary patterns among individuals with plasma cell disorders– opportunities for targeted interventions
Traore K, Castro F, Derkach A, Gorshein E, Serrano E, Taneja A, Hurtado Martínez J, Lesokhin A, Sahagun Sanchez Aldana A, Flores Pérez P, Usmani S, Ahlstrom J, Block T, Hydren J, Thomson C, Shah U. Dietary patterns among individuals with plasma cell disorders– opportunities for targeted interventions. Blood Cancer Journal 2026, 16: 42. PMID: 41888093, PMCID: PMC13022416, DOI: 10.1038/s41408-026-01468-0.Commentaries, Editorials and Letters
2025
Newly Diagnosed High‐Risk Multiple Myeloma: Outcomes and Management
Yasar F, Gorshein E. Newly Diagnosed High‐Risk Multiple Myeloma: Outcomes and Management. Advances In Hematology 2025, 2025: 6622365. PMID: 41048839, PMCID: PMC12494473, DOI: 10.1155/ah/6622365.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHigh-risk cytogenetic abnormalitiesAutologous stem cell transplantationHigh-risk MMMinimal residual diseaseMultiple myelomaChimeric antigen receptor T cellsHigh-risk multiple myelomaBispecific antibodiesAssociated with aggressive diseaseInferior progression-freeCAR-T cellsStem cell transplantationTransplant-ineligible patientsRisk-adapted approachHeterogeneous hematologic malignancyStandard of careProgression-FreeResidual diseaseCAR-TInduction regimensCytogenetic abnormalitiesFrontline therapyMaintenance therapyOverall survivalAggressive disease
2024
Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis
Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.Commentaries, Editorials and Letters
2023
“Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation
Chen P, Gorshein E, Tormey C, Siddon A, Perincheri S. “Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation. American Journal Of Hematology 2023, 98: 984-988. PMID: 36688500, DOI: 10.1002/ajh.26856.Peer-Reviewed Educational Materials
2016
Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental?
Zelefsky M, Kollmeier M, Gorshein E, Pei X, Torres M, McBride S, Happersett L, Cohen G, Yamada Y. Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental? Radiotherapy And Oncology 2016, 121: 109-112. PMID: 27756494, PMCID: PMC5546832, DOI: 10.1016/j.radonc.2016.08.010.Peer-Reviewed Original ResearchConceptsDegenerative joint diseaseHip painPersistent hip painSevere hip painLocalized prostate cancerOnly variableProstate cancer patientsExternal beam radiotherapyHip revision surgerySalvage therapySevere painCancer patientsProstate cancerJoint diseaseLower incidenceBeam radiotherapyHip replacementConcurrent ADTMultivariate analysisPatientsRadiotherapyPainProstate radiotherapyIncidenceAmbulation
2014
Clinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer
Gorshein E, Klein P, Boolbol S, Shao T. Clinical Significance of HER2-Positive and Triple-Negative Status in Small (≤ 1 cm) Node-Negative Breast Cancer. Clinical Breast Cancer 2014, 14: 309-314. PMID: 24703318, DOI: 10.1016/j.clbc.2014.02.007.Peer-Reviewed Original ResearchConceptsWorse RFSTN statusBreast cancerClinical significanceSmall node-negative breast cancersNode-negative breast cancer patientsSmall node-negative tumorsNode-negative breast cancerAggressive adjuvant therapyNode-negative tumorsTN breast cancerKaplan-Meier methodBreast cancer patientsTriple-negative statusAdjuvant chemotherapyAdjuvant therapyRFS ratesMedian ageReceptor statusTumor sizeCancer patientsTN tumorsPatientsService databaseMultivariate analysis
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
IRB ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
IRB ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
IRB ID2000025737RoleSub InvestigatorPrimary Completion Date12/31/2029Recruiting ParticipantsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
IRB ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting ParticipantsRandomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
IRB ID2000024170RoleSub InvestigatorPrimary Completion Date01/01/2035Recruiting Participants
Clinical Care
Overview
Elan Gorshein, DO (doctor of osteopathic medicine), MPH, specializes in treating patients with hematologic malignancies at Smilow Cancer Hospital.
Hematologic malignancies are cancers that begin in blood-forming tissue, such as bone marrow and immune system cells, and include leukemia, lymphoma, and multiple myeloma. Osteopathic medicine focuses on treating the patient as a whole rather than addressing specific symptoms.
Dr. Gorshein has a JD (juris doctor) degree and is an assistant professor of clinical medicine (hematology) at Yale School of Medicine.
Clinical Specialties
Hematologic Oncology; Thoracic Oncology
Fact Sheets
Thrombocytopenia
Learn More on Yale MedicineCOVID-19
Learn More on Yale MedicineCoronavirus
Learn More on Yale MedicineMyeloproliferative Neoplasms
Learn More on Yale Medicine
Yale Medicine News
News
News
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.